Health Condition 1: C00-D49- Neoplasms
Conditions
Interventions
Intervention1: Tablet Olanzapine 5mg: 1st day of anticancer chemotherapy- Tablet Olanzapine 5mg Once a day before chemo administration and regimen (Injection palonosetron 0.25mg once a day, Injection
Sponsors
Department of Pharmacology and Department of RadioOncology
Eligibility
Inclusion criteria
Inclusion criteria: 1-18 years of age or older patients who had not received previous chemotherapy 2-Patients going to receive 1st cycle of highly emetogenic cancer chemotherapy 3-Written informed consent. 4-Able to understand and describe patient-reported outcomes.
Exclusion criteria
Exclusion criteria: 1-History of hypersensitivity or allergy to any of antiemetic drugs we are going to use in study 2-Received any chemotherapy in last 3 weeks. 3-Multiday chemotherapy regimen, concurrent radiotherapy 4-brain metastasis
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| primary outcome- complete response of vomiting in early(0- 24hrs), delayed(24-120 hrs) in both groups Secondary outcome- to record different grades of chemotherapy induced nausea and vomiting in all three periodsTimepoint: early(0- 24hrs), delayed(24-120 hrs) and overall period (0-120hrs) | — |
Secondary
| Measure | Time frame |
|---|---|
| To record different grades of chemotherapy induced nausea and vomiting (CINV) in all three periods: - Acute (0- 24 hrs), Delayed (24 -120hrs), overall(0-120hrs).Timepoint: early(0- 24hrs), delayed(24-120 hrs) and overall period (0-120hrs) | — |
Countries
India
Contacts
Public ContactDr Abhay Pratap Singh
UPUMS, Saifai
Outcome results
None listed